Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D78CME
|
|||
| Drug Name |
TAVT-45
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 3 | [1] | |
| Company |
Tavanta Therapeutics King of Prussia, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [2] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Androgen biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| Prolactin signaling pathway | ||||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Steroidogenesis | ||||
| Reactome | Androgen biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| Steroid Biosynthesis | ||||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| Prostate Cancer | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04887506) Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Tavanta Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.